DEVELOPMENT OF PEDAGOGICAL TECHNOLOGIES IN
MODERN SCIENCES
International scientific-online conference
93
MODERN APPROACHES TO THE TREATMENT OF ARTHROPATHIC
PSORIASIS
Khudayberganova N.A.
Student of group MED-58 R, Faculty of General
Medicine, Kimyo International University in Tashkent
Adilov A.A.
student of group MED-82 E, Faculty of General
Medicine, Kimyo International University in Tashkent
B.S.Azizov
Scientific Supervisor: Associate Professor
Department of Dermatovenereology and Cosmetology
Tashkent State Dental Institute, Uzbekistan
https://doi.org/10.5281/zenodo.16353819
Relevance:
Arthropathic psoriasis (psoriatic arthritis) is a severe chronic
condition that occurs in approximately 20–30% of patients with psoriasis.
Without timely diagnosis and adequate therapy, it can lead to persistent joint
deformities, impaired work capacity, and disability. In recent years, significant
progress has been made in understanding the pathogenesis of the disease, which
has led to the development of new effective treatments, especially the use of
biologic agents. Given its high prevalence, the variety of clinical manifestations,
and the need for a multidisciplinary treatment approach, the study of
arthropathic psoriasis remains a highly relevant field in modern rheumatology
and dermatology.
Research Objective:
To examine modern treatment approaches for
arthropathic psoriasis and analyze their effectiveness based on recent data.
Research Methods:
The treatment of arthropathic psoriasis focuses on
suppressing inflammation, preventing the progression of structural joint
damage, and improving the patient’s quality of life. Current therapy includes
several key directions:
1.
Nonsteroidal anti-inflammatory drugs (NSAIDs):
Used in the
early stages to relieve pain and inflammation, but they do not affect disease
progression.
2.
Glucocorticosteroids:
Administered as local injections in cases of
limited joint inflammation. Systemic use is restricted due to the risk of
exacerbating skin psoriasis. Hormonal (corticosteroid) ointments include:
Clobetasol (Dermovate)
Betamethasone (Celestoderm, Diprolene)
Mometasone (Elocom)
Fluticasone (Cutivate)
DEVELOPMENT OF PEDAGOGICAL TECHNOLOGIES IN
MODERN SCIENCES
International scientific-online conference
94
3.
Conventional
disease-modifying
anti-rheumatic
drugs
(DMARDs):
Methotrexate – one of the most commonly used drugs.
Sulfasalazine, leflunomide, and cyclosporine – alternatives for patients
intolerant to methotrexate. These medications slow disease progression and are
used in peripheral arthritis forms.
4.
Biologic therapy:
Applied in moderate to severe cases, particularly
when DMARDs are ineffective. This includes:
TNF-α inhibitors (adalimumab, etanercept, infliximab)
IL-17 inhibitors (secukinumab, ixekizumab)
IL-12/23 inhibitors (ustekinumab)
IL-23 inhibitors (guselkumab, risankizumab)
JAK inhibitors (tofacitinib, upadacitinib) – used for resistant forms.
Biologic therapy offers a clear advantage by specifically blocking intracellular
inflammatory signaling pathways, thereby promoting targeted healing of
psoriatic skin lesions.
5.
Team-based (Multidisciplinary) approach:
Treatment involves
dermatologists, rheumatologists, physiotherapists, and, if necessary,
psychologists.
Conclusion:
Arthropathic psoriasis is a chronic immune-inflammatory condition that
combines skin symptoms of psoriasis with joint involvement, requiring a
comprehensive, individualized, and multidisciplinary treatment approach.
Modern treatment methods include the use of biologic agents such as TNF-α, IL-
17, and IL-23 inhibitors, which effectively control both skin and joint symptoms
of the disease. Personalized therapy selection, taking into account disease
activity, comorbidities, and prognostic factors, is becoming a key focus of
modern rheumatologic and dermatologic therapy. The advancement of biologics
and targeted therapy significantly improves patients' quality of life and slows
the progression of joint damage.
References:
1.
Gossec, L., Baraliakos, X., Kerschbaumer, A., et al. (2020). EULAR
recommendations for the management of psoriatic arthritis with
pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases,
79(6), 700–712. https://doi.org/10.1136/annrheumdis-2020-217159
2.
Singh, J. A., Guyatt, G., Ogdie, A., et al. (2019). 2018 American College of
Rheumatology/National Psoriasis Foundation guideline for the treatment of
DEVELOPMENT OF PEDAGOGICAL TECHNOLOGIES IN
MODERN SCIENCES
International scientific-online conference
95
psoriatic
arthritis.
Arthritis
&
Rheumatology,
71(1),
5–32.
https://doi.org/10.1002/art.40726
3.
Mease, P. J., Smolen, J. S., Behrens, F., et al. (2021). A head-to-head
comparison of IL-17A and TNF inhibitors in psoriatic arthritis: efficacy and
safety results from randomized clinical trials. The Lancet Rheumatology, 3(7),
e407–e417. https://doi.org/10.1016/S2665-9913(21)00120-4
4.
Coates, L. C., & Helliwell, P. S. (2020). Psoriatic arthritis: state of the art
review. Clinical Medicine, 20(1), 70–74. https://doi.org/10.7861/clinmed.2019-
0350
5.
Ogdie, A., & Weiss, P. (2015). The epidemiology of psoriatic arthritis.
Rheumatic
Disease
Clinics
of
North
America,
41(4),
545–568.
https://doi.org/10.1016/j.rdc.2015.07.001
6.
Gladman, D. D., Antoni, C., Mease, P., et al. (2005). Psoriatic arthritis:
epidemiology, clinical features, course, and outcome. Annals of the Rheumatic
Diseases, 64(Suppl 2), ii14–ii17. https://doi.org/10.1136/ard.2004.032482
7.
Ritchlin, C. T., Colbert, R. A., & Gladman, D. D. (2017). Psoriatic Arthritis.
New
England
Journal
of
Medicine,
376(10),
957–970.
https://doi.org/10.1056/NEJMra1505557
8.
McInnes, I. B., & Schett, G. (2017). Pathogenetic insights from the
treatment of psoriatic arthritis. The Lancet, 389(10086), 1337–1346.
https://doi.org/10.1016/S0140-6736(16)32461-6
9.
Mease, P. J., Rahman, P., Gottlieb, A. B., et al. (2020). Efficacy of
guselkumab, an IL-23 inhibitor, in psoriatic arthritis: results from a phase 3 trial.
Arthritis
&
Rheumatology,
72(10),
1793–1803.
https://doi.org/10.1002/art.41376
10.
Kavanaugh, A., & Helliwell, P. (2022). JAK inhibitors in psoriatic arthritis: a
new therapeutic option. Rheumatology (Oxford), 61(SI2), ii47–ii53.
https://doi.org/10.1093/rheumatology/keac203
